Welcome to our dedicated page for Cue Biopharma news (Ticker: CUE), a resource for investors and traders seeking the latest updates and insights on Cue Biopharma stock.
Cue Biopharma (CUE) operates in the clinical-stage biotechnology space, where news flow centers on scientific and regulatory developments. This page aggregates news coverage for the Cambridge-based immunotherapy company, which develops biologics targeting T cell modulation for cancer and autoimmune diseases.
For biotechnology investors tracking Cue Biopharma, the most significant news events typically include clinical trial data readouts, regulatory interactions with the FDA, and partnership announcements with larger pharmaceutical companies. The company's pipeline spans oncology programs like CUE-101 for HPV-positive cancers and CUE-102 for glioblastoma, as well as autoimmune programs like CUE-401.
Financial news for CUE covers quarterly earnings reports, capital raises, and updates on cash runway. As a clinical-stage company without product revenue, funding announcements and burn rate discussions are particularly relevant for assessing the company's ability to advance its programs through development milestones.
Bookmark this page to follow Cue Biopharma's progress as its therapeutic candidates advance through clinical development. News coverage includes earnings releases, conference presentations, trial updates, and strategic developments that shape the company's trajectory in the competitive immunotherapy landscape.
Cue Biopharma (CUE) has announced a presentation at the Biophysical Society Annual Meeting, highlighting a collaboration with the University of Oxford's Dr. Michael Dustin. This study focuses on the mechanisms of IL-2 in T cell immunological synapse formation, particularly regarding its CUE-100 series biologics. Lead candidate CUE-101 aims to enable selective T cell activation, strengthening its potential for treating tumors. The presentation will take place on February 20, 2022, at 1:45 p.m. PST.
Cue Biopharma (CUE) provided a clinical update on its lead candidate CUE-101, currently in a Phase 1b trial for HPV+ recurrent/metastatic head and neck cancer.
Early data from a combination study with KEYTRUDA® revealed positive outcomes, with two patients achieving partial responses and two showing lesion reductions.
Additionally, CUE-101 monotherapy demonstrated a 50% clinical benefit rate, enhancing overall survival rates by selectively stimulating CD8+ T cells.
Cue Biopharma, Inc. (CUE), a clinical-stage biopharmaceutical firm, announced a conference call and webcast for January 26, 2022, at 4:30 p.m. EST to provide updates on its clinical trials, particularly for CUE-101, its lead IL-2 based candidate targeting HPV+ recurrent/metastatic head and neck cancer. The call will discuss recent data from the Phase 1b trial and plans for CUE-102, along with strategic objectives and anticipated milestones. The event will be accessible live and archived on the company’s website.
On January 5, 2022, Cue Biopharma announced a major milestone in its collaboration with LG Chem Life Sciences regarding CUE-102, an Immuno-STAT™ biologic targeted at WT1-expressing cancers. The achievement paves the way for a planned IND submission to the FDA in Q1 2022 and includes a $3 million milestone payment from LG Chem. CEO Daniel Passeri expressed optimism about CUE-102's potential in treating solid tumors and hematologic malignancies. Preclinical data reinforces the versatility of the Immuno-STAT platform, aimed at advancing oncology therapies directly in patients.
On December 15, 2021, Cue Biopharma announced the appointment of Patricia Nasshorn as Chief Business Officer. Her extensive experience in business development and partnerships is expected to bolster the company’s growth, particularly amid promising data from the ongoing CUE-101 trial, which highlights the potential of their interleukin 2-based CUE-100 series in immuno-oncology. CEO Daniel Passeri expressed optimism about Nasshorn's contributions to Cue Biopharma’s strategic initiatives and future collaborations.
Cue Biopharma (Nasdaq: CUE) announced its participation in a fireside chat at the JMP Securities Hematology and Oncology Summit on December 6, 2021, from 11:40 a.m. to 12:10 p.m. EST. The session will feature a clinical update on CUE-101, its lead program, evaluating its effectiveness as a monotherapy and in combination with KEYTRUDA® for patients with HPV+ recurrent/metastatic head and neck cancer. The company will also discuss developments in its CUE-100 series pipeline. Interested parties can access the live and archived webcast on their website.
Cue Biopharma (CUE) announced its participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29 to December 2, 2021. The company will feature a pre-recorded fireside chat, available on its website starting November 22, 2021, at 10:00 a.m. EST. Cue Biopharma is focused on developing a novel class of injectable biologics that engage T cells, aiming to transform treatments for cancer and autoimmune diseases. The archived recording will be accessible for 90 days post-event.
Cue Biopharma (CUE) presented promising interim data for CUE-101, a monotherapy targeting HPV+ head and neck cancer, at SITC 2021. CUE-101 showed durable partial responses and favorable tolerability in its Phase 1 trial, with doses administered exceeding 190. Additionally, early results indicated potential activity when combined with pembrolizumab. CUE-102 demonstrated the ability to activate WT1-specific T cells, supporting its advancement towards clinical trials. The company plans to file for Investigational New Drug status for CUE-102 in Q1 2022, enhancing its development pipeline.
On November 10, 2021, Cue Biopharma (Nasdaq: CUE) announced its participation in two upcoming virtual fireside chats. The first will occur at the Stifel Healthcare Conference from November 15-17, while the second will take place at the Jefferies London Healthcare Conference from November 16-19. Cue Biopharma will update participants on its lead clinical program, CUE-101, and its related CUE-100 series pipeline, addressing treatments for HPV+ recurrent/metastatic head and neck cancer. Webcasts of these discussions will be available on the company's website.
Cue Biopharma announced promising findings from a study published in the Journal of Clinical Investigation, revealing that its Immuno-STAT™ Biologics can activate and expand anti-viral cytotoxic T cells targeting HIV and CMV. The study indicates potential for treating chronic viral infections without ex vivo manipulation of T cells, addressing a critical barrier in HIV treatment. Ongoing Phase 1 trials of CUE-101 also show positive outcomes in cancer therapy. The modularity of the Immuno-STAT platform suggests versatility in treating various infectious diseases.
FAQ
What is the current stock price of Cue Biopharma (CUE)?
What is the market cap of Cue Biopharma (CUE)?
